Shanghai Junshi Biosciences (SHJBF) News Today C$1.24 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Shanghai Junshi Biosciences Proposes New Board MembersNovember 29, 2024 | tipranks.comShanghai Junshi Unveils Strategic Financial DecisionsNovember 29, 2024 | tipranks.comShanghai Junshi Biosciences Relocates Key OfficesNovember 29, 2024 | tipranks.comShanghai Junshi Biosciences’ TUOYI Gains Key Insurance InclusionNovember 28, 2024 | tipranks.comShanghai A Share IndexNovember 6, 2024 | marketwatch.comJunshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAROctober 16, 2024 | markets.businessinsider.comJunshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China's Hong Kong SAROctober 15, 2024 | tmcnet.comJunshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For ToripalimabJuly 27, 2024 | markets.businessinsider.comWatch: Explore ShanghaiJuly 25, 2024 | bbc.co.ukShanghai Junshi Biosciences Co. Ltd.April 26, 2024 | wsj.comJunshi Biosciences Announces NDA Acceptance in Hong Kong for ToripalimabApril 24, 2024 | finance.yahoo.comJunshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences AuthorityFebruary 2, 2024 | finance.yahoo.comJunshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung CancerJanuary 18, 2024 | finance.yahoo.comShanghai Junshi Biosciences Co Ltd (1877)January 11, 2024 | investing.comJunshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature MedicineJanuary 10, 2024 | finance.yahoo.comShanghai LujianziJanuary 6, 2024 | forbes.comWhat to Eat in ShanghaiJanuary 5, 2024 | travel.usnews.comInovio stock surges to seven-month highJanuary 5, 2024 | msn.comJunshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC PatientsJanuary 2, 2024 | finance.yahoo.comHow long will Shanghai's lockdown last?December 12, 2023 | bbc.comWeek In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/DivestmentsDecember 3, 2023 | seekingalpha.comJunshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGADecember 1, 2023 | finance.yahoo.comCoherus cancer drug undercuts Merck's KeytrudaNovember 28, 2023 | msn.comJunshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19November 22, 2023 | finance.yahoo.comCoherus, Shanghai Junshi Shares Gain After U.S. Approval For Nasopharyngeal Cancer DrugOctober 31, 2023 | msn.comJunshi-Coherus' Loqtorzi cancer drug wins FDA approvalOctober 30, 2023 | msn.comJunshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023October 27, 2023 | finance.yahoo.comJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung CancerJuly 19, 2023 | finance.yahoo.comShanghai Junshi Biosciences Co Ltd Class HJuly 15, 2023 | morningstar.comJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application for ToripalimabJuly 11, 2023 | finance.yahoo.comShanghai OPM Biosciences Co. Ltd. AJune 19, 2023 | wsj.comJunshi's toripalimab gets Chinese regulator review for expanded use in breast cancerMay 23, 2023 | seekingalpha.comJunshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast CancerMay 23, 2023 | finance.yahoo.comShanghai OPM Biosciences Co Ltd (688293)May 18, 2023 | investing.comShanghai Junshi Biosciences Co Ltd (688180)May 11, 2023 | investing.comJunshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 CountriesMay 7, 2023 | tmcnet.comJunshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell CarcinomaApril 27, 2023 | marketwatch.comJunshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch StudyApril 20, 2023 | finance.yahoo.comGet Ready For Ethereum’s Shanghai UpgradeApril 14, 2023 | forbes.comJunshi Biosciences Announces Phase 3 Clinical Study ofApril 12, 2023 | tmcnet.comJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC PatientsApril 12, 2023 | finance.yahoo.comJunshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary EndpointApril 12, 2023 | finance.yahoo.comShanghai Junshi Biosciences Co., Ltd. (SHJBF)March 31, 2023 | finance.yahoo.comJunshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical StudiesFebruary 28, 2023 | finance.yahoo.comShanghai Junshi Biosciences Co LtdFebruary 17, 2023 | reuters.comJunshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal CarcinomaFebruary 15, 2023 | finance.yahoo.comJunshi Biosciences Announces Approval for Marketing of VV116 in ChinaJanuary 30, 2023 | finance.yahoo.comJunshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical StudyJanuary 18, 2023 | finance.yahoo.comJunshi Biosciences Announces Acceptance of NDA for VV116 in ChinaJanuary 18, 2023 | finance.yahoo.com Get Shanghai Junshi Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SHJBF and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW SHJBF Media Mentions By Week SHJBF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SHJBF News Sentiment▼0.000.60▲Average Medical News Sentiment SHJBF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SHJBF Articles This Week▼00▲SHJBF Articles Average Week Get Shanghai Junshi Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SHJBF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Arno Therapeutics News Ascentage Pharma Group International News Ascletis Pharma News Avacta Group News Awakn Life Sciences News AXIM Biotechnologies News BriaCell Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SHJBF) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shanghai Junshi Biosciences Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shanghai Junshi Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.